Evidence map›Paper›PMID 40662763›Full record

ArticleJournal of clinical microbiology2025

Class and isotype of VlsE-specific antibody differentiates Lyme disease stage.

Nisha Nair, Adriana Marques, Elizabeth J Horn, Grant Brown, Maria Gomes-Solecki

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Protective efficacy of mutant strains ofInfection and immunity · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Nisha NairDepartment of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Adriana MarquesLyme Disease Studies Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA.ORCID 0000-0002-5403-4551
Elizabeth J HornLyme Disease Biobank, Portland, Oregon, USA.
Grant BrownDepartment of Biostatistics, University of Iowa, Iowa City, Iowa, USA.ORCID 0000-0002-7247-7313
Maria Gomes-SoleckiDepartment of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-3715-4543

Funding

Intranasal Vaccine Against Lyme DiseaseR44AI167605 · NIAID · IMMUNO TECHNOLOGIES, INC. · PI GOMES-SOLECKI, MARIA · 2022 to 2024
$3.0M
Antibody isotyping for discrimination of disease stage and diagnosis of early Lyme disease.R43AI155211 · NIAID · IMMUNO TECHNOLOGIES, INC. · PI GOMES-SOLECKI, MARIA · 2020 to 2021
$594k
National Institute of Allergy and Infectious Diseases NANational Institute of Allergy and Infectious Diseases R43AI155211NIAID NIH HHS R43 AI155211NIAID NIH HHS R44 AI167605
6 · The paper itself

Abstract

Establishment of immunoglobulin diversity is contingent on recombination that occurs both at the Fab and at the Fc regions of the immunoglobulin, and this process is time dependent. Based on this principle, we questioned whether Lyme disease stage can be distinguished by quantification of immunoglobulin class and IgG isotype specific to VlsE in serum from clinically characterized patients. We used an enzyme immunoassay to categorize serologic antibodies to VlsE antigen as well as machine-learning techniques to train and integrate multiple predictors to identify likely disease stage. We found that IgM/IgG3/IgG1/IgA1 was enriched in serum obtained in the earliest stages, whereas IgG3/IgG1/IgG4 was enriched in Lyme arthritis. IgG2 detection was unremarkable across all disease stages. Post-Treatment Lyme Disease Syndrome (PTLDS) serum was enriched in IgG3/IgG1/IgA1 but lacked IgM. The multivariable models showed better predictive accuracy than any single immunoglobulin model, with more than half of panels perfectly identified by random forest under cross validation (56%) vs a maximum of 38% for a model using IgG1 alone. The findings suggest a characteristic succession of VlsE-specific antibody switching between immunoglobulin class and IgG isotype as Lyme disease progresses from early to late stages. The data also suggest that immunoglobulin class and IgG isotyping are likely more helpful to distinguish early Lyme disease cases. Comprehensive evaluation of immunoglobulin class (M, G, A) and IgG isotypes (1/2/3/4) provides time-dependent pathogen-induced host response information to current Lyme disease antibody detection and may be useful for differentiation of disease stage. IMPORTANCE: The order of switching between the immunoglobulin heavy chain (Fc) is time dependent, progressing from IgM/D to IgG3/IgG1/IgA1/IgG2/IgG4 and later to IgE/IgA2. In this study, we show that

Indexed as

Antibodies, BacterialAntigens, BacterialBacterial ProteinsBorrelia burgdorferiImmunoglobulin IsotypesLipoproteinsLyme DiseaseAdultFemaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedAntibodies, BacterialAntigens, BacterialBacterial ProteinsImmunoglobulin GImmunoglobulin IsotypesImmunoglobulin MLipoproteinsVlsE protein, Borrelia burgdorferiantibodyBorrelia burgdorferidisease progressionearly diagnosiserythema chronicum migransimmunoglobulin class switchingimmunoglobulin isotypeslyme diseasePTLDStimeVlsE

Identifiers

PMID40662763
PMCPMC12345165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.